Systemic Therapy for Hereditary Breast Cancers

Harvey-Jones, Elizabeth; Lord, Christopher J.; Tutt, Andrew N.J.

doi:10.1016/j.hoc.2022.08.018

Cited by 2 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its patterns and trends vary in distinct countries, being the second driving cause of cancer death among women overall—after lung cancer—and the head cause of cancer death in Africa and America among Black and Hispanic women [ 4 , 5 ]. About 5–10% of all BC patients are genetically predisposed to cancers [ 6 , 7 ] and almost 80% of patients with BC are individuals aged >50. Nevertheless, BC is the most common cancer diagnosed and the second most common cause of cancer death in women aged less than 40 years [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of cancer death among women worldwide. Globally, BC is the second most frequent cancer and first most frequent gynecological one, affecting women with a relatively low case-mortality rate. Surgery, radiotherapy, and chemotherapy are the main treatments for BC, even though the latter are often not aways successful because of the common side effects and the damage caused to healthy tissues and organs. Aggressive and metastatic BCs are difficult to treat, thus new studies are needed in order to find new therapies and strategies for managing these diseases. In this review, we intend to give an overview of studies in this field, presenting the data from the literature concerning the classification of BCs and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Germline pathogenic variants among high hereditary risk patients with breast and ovarian cancer and unaffected subjects in Lebanese Arab women

Moukadem,

Fakhreddine,

Assaf

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

BACKGROUND The prevalence of germline pathogenic variants in high hereditary risk breast and/or ovarian cancer patients and unaffected subjects referred for testing is an unmet need in low and middle-income countries. AIM To determine the prevalence of germline pathogenic variants in high hereditary risk patients with breast and/or ovarian cancer and unaffected individuals. METHODS We retrospectively reviewed records of patients and unaffected subjects referred for germline pathogenic variant testing due to high hereditary risk between 2010-2020. Data was collected and analyzed on Excel sheet. RESULTS In total, 358 individuals were included, including 257 patients and 101 unaffected individuals with relatives with breast or ovarian cancer. The prevalence of breast cancer susceptibility gene (BRCA) 1/2 pathogenic variants was 8.63% (19/220) in patients with breast cancer, and 15.1% (5/33) in those with ovarian cancer. Among the 25 of 220 patients with breast cancer tested by next-generation sequencing, 3 patients had pathogenic variants other than BRCA1/2 . The highest risk was observed in those aged 40 years with breast cancer and a positive family history, where the BRCA1/2 prevalence was 20.1% (9/43). Among the unaffected subjects, 31.1% (14/45) had the same BRCA1/2 pathogenic variants in their corresponding relatives. Among the subjects referred because of a positive family history of cancer without known hereditary factors, 5.35% (3/56) had pathogenic variants of BRCA1 and BRCA2 . The c.131G>T nucleotide change was noted in one patient and two unrelated unaffected subjects with a BRCA1 pathogenic variant. CONCLUSION This study showed a 8.63% prevalence of pathogenic variants in patients with breast cancer and a 15.1% prevalence in patients with ovarian cancer. Among the relatives of patients with BRCA1/2 pathogenic variants, 31% tested positive for the same variant, while 5.3% of subjects who tested positive due to a family history of breast cancer had a BRCA pathogenic variant.

show abstract

Systemic Therapy for Hereditary Breast Cancers

Cited by 2 publications

References 105 publications

Targeting Breast Cancer: An Overlook on Current Strategies

Targeting Breast Cancer: An Overlook on Current Strategies

Germline pathogenic variants among high hereditary risk patients with breast and ovarian cancer and unaffected subjects in Lebanese Arab women

Contact Info

Product

Resources

About